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PHeart Rhythm Disorders
icrovolt T-Wave Alternans for the Risk
tratification of Ventricular Tachyarrhythmic Events
Meta-Analysis
nil K. Gehi, MD,* Russell H. Stein, MD,† Louise D. Metz, MD,‡ J. Anthony Gomes, MD, FACC*
ew York, New York
OBJECTIVES The objective of this study was to perform a meta-analysis of the predictive value of microvolt
T-wave alternans (MTWA) testing for arrhythmic events in a wide variety of populations.
BACKGROUND Previous studies describing the use of MTWA as a predictor of ventricular tachyarrhythmic
events have been limited by small sample sizes and disparate populations.
METHODS Prospective studies of the predictive value of exercise-induced MTWA published between
January 1990 and December 2004 were retrieved. Data from each article were abstracted
independently by two authors using a standardized protocol. Summary estimates of the
predictive value of MTWA were made using a random-effects model.
RESULTS Data were accumulated from 19 studies (2,608 subjects) across a wide range of populations.
Overall, the positive predictive value of MTWA for arrhythmic events was 19.3% at an
average of 21 months’ follow-up (95% confidence interval [CI] 17.7% to 21.0%), the negative
predictive value was 97.2% (95% CI 96.5% to 97.9%), and the univariate relative risk of an
arrhythmic event was 3.77 (95% CI 2.39 to 5.95). There was no difference in predictive value
between ischemic and nonischemic heart failure subgroups. The positive predictive value
varied depending on the population of patients studied (p  0.0001).
CONCLUSIONS Microvolt T-wave alternans testing has significant value for the prediction of ventricular
tachyarrhythmic events; however, there are significant limitations to its use. The predictive
value of MTWA varies significantly depending on the population studied. Careful standard-
ization is needed for what constitutes abnormal MTWA. The incremental prognostic value
of MTWA when used with other methods of risk stratification is unclear. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.059Cardiol 2005;46:75–82) © 2005 by the American College of Cardiology Foundation
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phe risk stratification of patients for sudden cardiac death
SCD) is a major challenge in clinical medicine. Although
e have made advances in the area of risk stratification, it
emains troubling that the majority of individuals who die of
CD are among a population not identified by current
ethods of risk stratification (1). As pointed out by Huikuri
t al. (1) and Buxton (2), evidence suggests that ejection
raction (EF) alone lacks sufficient sensitivity and specificity
o be a useful single method of risk stratification.
The assessment of microvolt T-wave alternans (MTWA)
as been proposed as a method to detect abnormalities in
entricular repolarization that may predict the occurrence of
entricular reentrant arrhythmias (3). Electrical alternans is
efined as beat-to-beat changes in the amplitude of the
lectrocardiogram (ECG) signal. The presence of alternans
f the T-wave amplitude at a 0.5 cycle-per-beat periodicity
efines T-wave alternans. Measurement of T-wave alter-
ans at the microvolt level was first described by Adam et al.
4). The first clinical description of using MTWA to predict
he occurrence of ventricular tachyarrhythmias was per-
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niversity Medical Center, New York, New York.p
Manuscript received January 30, 2005; revised manuscript received February 22,
005, accepted March 22, 2005.ormed by Rosenbaum et al. (5). After this description, the
ethodology of MTWA assessment was standardized (6).
ith increasing heart rate achieved through atrial pacing,
obutamine, or exercise, sequential ECG cycles are aligned
o their QRS complex, and the T-wave amplitude is
easured. The beat-to-beat fluctuations in amplitude are
pectrally analyzed using a fast Fourier transformation. The
resence of significant MTWA is defined as an alternans
oltage 1.9 V at 0.5 cycles-per-beat with an alternans
atio 3. The absence of MTWA is defined as no evidence
f alternans at 0.5 cycles-per-beat when the heart rate is
ustained 105 beats/min or within 5 beats/min of maxi-
um predicted heart rate for at least 1 min. Otherwise,
TWA is considered indeterminate. Whether or not an
ndeterminate MTWA assessment should be considered
bnormal or excluded altogether remains a methodologic
ssue (7).
Since its initial description, a number of studies have
escribed the use of MTWA as a predictor of the primary
r secondary occurrence of ventricular arrhythmic events.
hese studies, however, have been limited by small sample
izes and disparate patient populations. We, therefore,
erformed this systematic review and meta-analysis of
TWA as a predictor of arrhythmic events to clarify the
redictive accuracy and usefulness of MTWA for clinical
ractice.
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tudy selection. We performed a literature search using
he PubMed and Cochrane databases to identify articles
ublished between January 1990 and December 2004 of the
redictive value of exercise-induced MTWA in humans.
he following medical subject heading search terms were
sed: prospective studies, follow-up studies, predictive value
f tests, arrhythmia, sudden death, ventricular tachycardia,
entricular fibrillation. In addition, we used the search term
-wave alternans. The search was restricted to English
anguage literature and human subjects. The date limits
ere chosen because MTWA testing was not in clinical use
efore 1994. A second search of articles published by
uthors identified in the initial search and a review of the
ibliographies of all articles were performed to identify
dditional articles for review.
Studies were included if they met the following criteria:
) were prospective cohort studies of 10 human subjects
ho underwent exercise-induced MTWA testing for the
rediction of SCD or ventricular arrhythmias; 2) provided
rimary data on results of MTWA and of clinical outcomes,
ncluding SCD, cardiac death, ventricular arrhythmias,
nd/or implantable cardioverter-defibrillator (ICD) shock;
) provided clear definition of normal or abnormal MTWA
esting; and 4) had a follow-up time of six months or longer.
Two investigators (A.G. and R.S.) independently re-
iewed the titles and abstracts of these articles and excluded
hose that clearly did not meet the inclusion criteria. A
onsensus was reached on which articles should be com-
letely reviewed for potential inclusion in this study.
ata abstraction. Two investigators (A.G. and R.S.) in-
ependently reviewed potential articles blinded to the au-
hor, journal, and institution. Data for each article were
bstracted, including inclusion criteria, study design, patient
haracteristics (number, mean age, percent men, population
f patients), selection criteria (including inclusion/exclusion
riteria), details of MTWA assessment (including definition
f abnormal test), end points of the study, average follow-
p, raw data when provided, and reported findings, includ-
ng positive predictive value (PPV) and negative predictive
Abbreviations and Acronyms
CI  confidence interval
ECG  electrocardiogram
EF  ejection fraction
ICD  implantable cardioverter-defibrillator
MI  myocardial infarction
MTWA  microvolt T-wave alternans
NPV  negative predictive value
PPV  positive predictive value
RR  relative risk
SCD  sudden cardiac death
VF  ventricular fibrillation
VT  ventricular tachycardiaalue (NPV), relative risk (RR), or hazard ratios of future rardiac events. Results were stratified by definition of
bnormal MTWA (including or excluding indeterminate
TWA) when provided.
A quality analysis was performed based on the following
ssessment of the articles: 1) whether follow-up was com-
lete for 90% of the cohort, 2) whether adjudication of
utcomes was blinded to the results of MTWA testing, and
) whether a multivariate analysis using other standard
redictors of ventricular arrhythmic events performed was
sed. A study was considered at least of fair quality if it
ulfilled the criteria for 90% follow-up. A study was
onsidered good if one of the other two criteria was met.
tatistical analysis. The outcomes of each study were
resented as PPV, NPV, and univariate RR with confidence
ntervals (CIs) of MTWA for the prediction of ventricular
rrhythmic events at follow-up. Because of the inconsistent
se of the definition of abnormal MTWA (including or
xcluding indeterminate MTWA), outcomes for each study
ere stratified by this definition. Studies that assessed
TWA and outcomes in different patient populations were
resented individually for each patient population.
Summary estimates of the predictive value of ventricular
rrhythmic events were made using the DerSimonian and
aird (8) meta-analytic statistical method, which is based
n a random effects model. For consistency in the definition
f abnormal MTWA, summary estimates were calculated
efining abnormal MTWA excluding indeterminate
TWA tests, which was available for all the included
tudies. A sensitivity analysis based on the definition of an
bnormal test (including or excluding indeterminate test as
bnormal) was performed on the studies that provided these
ata to see whether this would affect the predictive value of
he test. Subgroup summary estimates were calculated based
n patient population (heart failure, ischemic heart failure,
onischemic heart failure, post-myocardial infarction
MI]), history of arrhythmic events (primary vs. secondary
revention), and quality of study (excluding fair quality
tudies).
A test for homogeneity using the Mantel-Haenszel (9)
ethod was performed for all summary estimates to evalu-
te the uniformity of findings across studies. A p value
0.10 was considered statistically significant to reject the
ull hypothesis of the test of homogeneity. Publication bias
as assessed using a funnel plot and the correlation coeffi-
ient, Kendall’s tau, comparing sample size to RR (10).
ESULTS
n initial literature search using the previously mentioned
earch terms identified 2,853 potential articles for inclusion
n this study. After reviewing and eliminating clearly ineli-
ible studies by review of titles and abstracts, 27 articles
ere identified for full review (5,11–36). A search of the
iterature of each author and a review of the bibliographies
f these articles identified an additional four articles for
eview (37–40). From these 31 articles, 14 were eliminated
f
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July 5, 2005:75–82 Microvolt T-Wave Alternans Meta-Analysisrom the meta-analysis: five studies were not prospective
12,16,19,35,38), five studies did not use primary data
21,22,27,29,34), two studies assessed pacing-induced
-wave alternans (5,25), one study had less than six months
f follow-up (18), and one study did not provide enough
rimary data (31). An attempt was made to contact the
uthor of the study that did not provide enough data (31).
rom the remaining 17 studies, two studies that provided
ndependent data on two different patient populations were
eparated in the analysis (15,32), which yielded a total of 19
tudies in this meta-analysis. Of these 19 studies, eight
rovided outcomes for participants with indeterminate
TWA, allowing us to calculate the predictive value of
bnormal MTWA including or excluding indeterminate
TWA.
The 19 prospective studies of MTWA (Table 1) included
,608 subjects. The mean age of the study participants
anged from 25 to 64 years. The average follow-up was 21
onths. The mean percentage of men ranged from 68 to
00. There was a wide range of subject populations, includ-
ng congestive heart failure (CHF), ischemic CHF, non-
schemic CHF, post-MI, athletes, and healthy subjects. The
ean EF of the study participants ranged from 23 to 71.
everal of the studies included only subjects with a history of
CD, ventricular fibrillation (VF), and ventricular tachycar-
ia (VT). Several of the studies included only subjects who
ere referred for an electrophysiologic study (indications
ncluded SCD, VF, VT, non-sustained VT, syncope, and
alpitations).
Results of the individual studies are presented in Table 2.
ositive predictive value at follow-up ranged from 0% to
7%, NPV ranged from 71% to 100%, and RR for having a
able 1. Characteristics of 19 Prospective Studies of Microvolt T
Author (Ref.)
Total
(n)
Mean
Age
(yrs)
Men
(%) Population
ohnloser et al. (11) 62 60 81 ICD recipients
ennersdorf et al. (15) 16 44 68 Nonischemic CHF
ennersdorf et al. (15) 44 49 70 Nonischemic CHF
lingenheben et al. (26) 107 56 80 CHF
dachi et al. (36) 64 53 81 Non-ischemic CHF
chwab et al. (39) 104 60 76 Post-MI
apaneinen et al. (40) 246 62 72 Post-MI
akabe et al. (13) 30 53 91 Non-ischemic CHF
akabe et al. (14) 41 54 80 CHF
keda et al. (28) 834 63 84 Post-MI
itamura et al. (37) 83 52 81 Nonischemic CHF
rimm et al. (23) 110 45 69 Healthy
rimm et al. (24) 263 48 73 Nonischemic CHF
ohnloser et al. (29) 137 55 77 Nonischemic CHF
arzi Braga et al. (17) 46 59 89 CHF
ashba et al. (20) 144 64 81 Ischemic CHF
urlanello et al. (32) 48 25 100 Healthy
urlanello et al. (32) 52 28 90 Athletic heart
loomfield et al. (33) 177 61 85 Ischemic CHF
A total of 24% of subjects had a history of an arrhythmic event in this study
CHF  congestive heart failure; EF  ejection fraction; ICD  implantable cardiover
ardiac death; VF  ventricular fibrillation; VT  ventricular tachycardia.ardiac event ranged from 0.85 to . In two studies, there
ere no events at follow-up such that an RR of events could
ot be calculated (23,32). All results presented exclude
ubjects with indeterminate MTWA tests.
Summary estimates of the PPV, NPV, and univariate RR
f MTWA for arrhythmic events, excluding indeterminate
TWA, in the 19 studies included in the meta-analysis are
resented in Table 3. The summary PPV during the average
1-month follow-up was 19.3% (95% CI 17.7% to 21.0%),
PV was 97.2% (95% CI 96.5% to 97.9%), and the
nivariate RR was 3.77 (95% CI 2.39 to 5.95).
Summary estimates of the PPV, NPV, and univariate RR
or arrhythmic events in several subgroup populations also
re presented in Table 3. In the subgroup of subjects with
HF (ischemic or nonischemic), the summary PPV during
he average 18 months’ follow-up was 25.5% (95% CI
2.7% to 28.3%), NPV was 93.8% (95% CI 92.3% to
5.4%), and the univariate RR was 2.51 (95% CI 1.71 to
.65) (Fig. 1). There was no significant difference in the
PV, NPV, or RR of MTWA testing between subjects with
schemic and non-ischemic CHF (p  0.10) (Table 3). In
ubjects after MI, the summary PPV during the average 18
onths’ follow-up was 6.0% (95% CI 4.5% to 7.4%), NPV
as 99.4% (95% CI 98.9% to 99.9%), and the univariate RR
as 4.74 (95% CI 1.11 to 20.19) (Fig. 2). There was no
ignificant difference in the NPV or RR of MTWA testing
etween CHF and post-MI subjects (p  0.10). However,
bnormal MTWA had a significantly higher PPV for
rrhythmic events at an average 18 months’ follow-up in
ubjects with CHF compared with post-MI (25.5% vs.
.0%, p  0.0001).
Summary estimates of MTWA for predicting arrhythmic
ve Alternans
an
F
) End Point
History of
Arrhythmic
Event?
Average
Follow-Up
(months) Quality
ICD event Yes 15 Good
.6 VT/VF Yes 6 Fair
.5 VT/VF No 6 Fair
SCD/VT/VF No 21 Good
A SCD/VT/VF No 24 Good
SCD/VT/VF No 15 Fair
Cardiac death No 14 Good
VT No 13 Fair
VT/VF Yes 13 Good
SCD/VF No 25 Good
A SCD/VT/VF No 21 Good
SCD/VT/VF No 32 Good
SCD/VT/VF No 52 Good
SCD/VT/VF Yes* 15 Good
Cardiac death No 19 Fair
SCD/VT/VF/ICD shock Yes 17 Good
A Syncope/VT No 36 Good
A Syncope/VT Yes 25 Good
Death No 20 Good-Wa
Me
E
(%
36
55
59
28
N
56
45
33
48
51
N
71
30
29
29
28
N
N
23ter-defibrillator; MI  myocardial infarction; NA  not available; SCD  sudden
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Microvolt T-Wave Alternans Meta-Analysis July 5, 2005:75–82vents in subjects with and without a history of arrhythmic
vents (primary or secondary events) are presented in Table 4.
n the subgroup with a history of arrhythmic events, the
ummary PPV at an average of 15 months’ follow-up was
1.0% (95% CI 45.1% to 56.9%), NPV was 86.0% (95% CI
2.0% to 90.1%), and the univariate RR was 2.45 (95% CI
.53 to 3.95). In the subgroup with no history of arrhythmic
vents, the summary PPV at an average of 22 months’
ollow-up was 15.4% (95% CI 13.8% to 17.0%), NPV was
8.1% (95% CI 97.5% to 98.7%), and the univariate RR was
.07 (95% CI 2.35 to 7.06). In the subgroup of subjects with
HF and no history of arrhythmic events, the summary
PV at an average 22 months’ follow-up was 20.9% (95%
I 17.8% to 24.0%), NPV was 96.3% (95% CI 94.8% to
7.7%), and the univariate RR was 3.81 (95% CI 1.86 to
.82). In the subgroup of subjects post-MI with no history
f arrhythmic events, the summary PPV at an average 18
onths’ follow-up was 6.0% (95% CI 4.5% to 7.4%), NPV
as 99.4% (95% CI 98.9% to 99.9%), and the univariate RR
as 4.74 (95% CI 1.11 to 20.19). There was no significant
ifferences in the NPV or RR of MTWA testing between
hese subgroups (p 0.10). However, the PPV for arrhyth-
Table 2. Results of 19 Prospective Studies of M
Author (Ref.)
PPV (%)
(95% CI)
Hohnloser et al. (11) 67 (55–79)
Hennersdorf et al. (15) 30 (8–52)
Hennersdorf et al. (15) 0 (0–0)
Klingenheben et al. (26) 21 (12–30)
Adachi et al. (36) 30 (19–41)
Schwab et al. (39) 4 (0–7)
Tapaneiner et al. (40) 0 (0–0)
Sakabe et al. (13) 54 (36–72)
Sakabe et al. (14) 67 (52–81)
Ikeda et al. (28) 7 (5–9)
Kitamura et al. (37) 23 (15–33)
Grimm et al. (23) 0 (0–0)
Grimm et al. (24) 13 (9–18)
Hohnloser et al. (29) 22 (14–30)
Sarzi Braga et al. (17) 29 (15–44)
Rashba et al. (20) 40 (31–49)
Furlanello et al. (32) 0 (0–0)
Furlanello et al. (32) 57 (43–71)
Bloomfield et al. (33) 14 (8–21)
*No arrhythmic events at follow-up.
CI  confidence interval; NA  not available; NPV 
relative risk.
able 3. Summary Estimates of PPV, NPV, and Univariate RR i
rediction of Cardiac Arrhythmic Events
Summary Estimates
PPV (%)
(95% CI)
NPV (%)
(95% CI)
ll studies 19.3 (17.7 to 21.0) 97.2 (96.5 to 97
ubgroups
CHF 25.5 (22.7 to 28.3) 93.8 (92.3 to 95
Ischemic CHF 29.7 (23.5 to 35.8) 91.6 (87.8 to 95
Non-ischemic CHF 21.3 (17.8 to 24.7) 95.2 (93.5 to 97
Post-MI 6.0 (4.5 to 7.4) 99.4 (98.9 to 99HF  congestive heart failure; CI  confidence interval; MI  myocardial infarction; oic events at follow-up of MTWA was significantly differ-
nt in these subgroups (51.0% vs. 20.9% vs. 6.0%, p 
.0001; Fig. 3).
Three studies performed a multivariate Cox regression
nalysis to determine the independent predictive value of
everal commonly used tests for risk stratification of ar-
hythmic events including MTWA (Table 5) (28,36,37). In
hese three studies, MTWA was independently predictive
f arrhythmic events in adjusted analysis. A sensitivity
nalysis of the summary estimates from the eight studies
hich included outcomes for subjects with indeterminate
TWA demonstrated no significant difference in whether
r not indeterminate MTWA was included in the definition
f an abnormal test (p  0.05).
None of the 19 studies were of poor quality. We found
o difference in the summary estimates of the PPV, NPV,
r RR of MTWA when excluding fair quality studies (p
0.10). The Mantel-Haenszel test for homogeneity was
0.10 for all summary estimates such that the combined
tudies were always homogeneous. Using a funnel plot
nd the correlation coefficient Kendall’s tau, we found no
volt T-Wave Alternans
NPV (%)
(95% CI)
RR
(95% CI)
73 (62–84) 2.5 (0.35–17.75)
100 (100–100) 4.45 (0.27–73.81)
100 (100–100) 
100 (100–100) 
97 (93–100) 10.2 (1.37–75.89)
99 (96–100) 2.66 (0.29–24.51)
99 (98–100) 0.85 (0.04–20.51)
100 (100–100) 
71 (57–85) 2.16 (1.02–4.58)
100 (99–100) 11.4 (3.4–37.9)
97 (94–100) 8.8 (1.2–65.4)
100 (100–100) *
90 (86–94) 1.3 (0.59–2.90)
94 (90–99) 3.44 (0.03–459.0)
100 (100–100) 
84 (77–91) 2.2 (1.1–4.7)
100 (100–100) *
100 (100–100) 
96 (93–100) 3.55 (0.89–14.11)
e predictive value; PPV  positive predictive value; RR 
Prospective Studies of Microvolt T-Wave Alternans for the
RR
(95% CI)
Average Follow-Up
(months) No. Studies
3.77 (2.39 to 5.94) 21 19
2.51 (1.71 to 3.65) 18 12
2.42 (1.30 to 4.50) 19 2
3.67 (1.50 to 8.96) 20 7
4.74 (1.11 to 20.19) 18 3icron 19
.9)
.4)
.3)
.0)
.9)ther abbreviations as in Table 2.
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July 5, 2005:75–82 Microvolt T-Wave Alternans Meta-Analysisvidence of publication bias in this meta-analysis (p 
.159).
ISCUSSION
e conducted the first meta-analysis of MTWA as a
redictor of arrhythmic events in a wide variety of patient
opulations, accumulating prospective data on more than
,600 subjects. Overall, we have found that the presence of
ignificant MTWA predicted a nearly four-fold risk of a
entricular arrhythmic event compared with the absence of
ignificant MTWA. The absence of MTWA carries a 3%
isk of arrhythmic events during an average of 21 months’
ollow-up. The presence of MTWA predicts a ventricular
rrhythmic event in 19% of subjects during an average of 21
onths’ follow-up. We found no difference in the predictive
alue of MTWA between patients with ischemic and
onischemic CHF. We found that the PPV of MTWA
epends significantly on the population being studied. In
he three studies that performed a multivariate analysis of
ommonly used methods of risk stratification, MTWA
emained significantly predictive of events after adjustment
or the predictive value of other methods, including EF.
hen comparing studies that provided outcomes data
lassifying abnormal MTWA as including or excluding
ndeterminate MTWA, we found no difference in the
verall PPV, NPV, or RR of abnormal MTWA.
Figure 1. Summary estimate of the relative risk of abnormal mc
igure 2. Summary estimate of the relative risk of abnormal microvolt
-wave alternans in subjects after myocardial infarction.Bailey et al. (41), in a meta-analysis, studied the testing
haracteristics of several other methods of risk stratification
or arrhythmic events, including EF, ambulatory ECG,
eart rate variability, signal-averaged ECG, and electro-
hysiologic study. The predictive value of these methods
aried with PPV, ranging from 13.3% to 25.8% at an
verage of two years of follow-up, NPV ranging from
4.52% to 96.12%, and univariate RR ranging from 2.9 to
.6 with no particular test having exceptional predictive
alue compared with the others. We found MTWA to have
imilar testing characteristics to these previous methods of
isk stratification, suggesting that MTWA should be con-
idered at least equivalent in its prognostic value.
Clinically, accepting a 97% NPV, one could sufficiently
lassify a patient with absent MTWA as “low risk” for
rrhythmic events. In our review, MTWA was absent in
5% to 54% of subjects, which was a substantial proportion
f subjects. However, when deciding which patients should
eceive an internal ICD for primary prophylaxis, the PPV of
rrhythmic events is more clinically relevant. Overall, the
PV for MTWA at 21 months’ follow-up was 19%. When
e excluded the patients with a history of arrhythmic events
ho had a high enough pretest probability to warrant an
CD, the PPV for MTWA decreased to 15%. From this
tandpoint, MTWA seems no better than the 20% PPV of
low EF reported in the meta-analysis of Bailey et al. (41).
Bailey et al. (41) ultimately suggest that a combination of
oninvasive risk stratification tests may be the most feasible
trategy to risk stratify a large proportion of patients into
igh- and low-risk categories. As demonstrated in the
tudies we reviewed that performed a multivariate analysis
Table 5), MTWA adds incremental prognostic value to
ther commonly used method of risk stratification. How-
ver, the additional absolute prognostic value is not clear
rom present studies.
It must be emphasized that the predictive value of
TWA testing varies depending on the pretest proba-
ility for arrhythmic events of the population being
tudied (spectrum bias). This variation is demonstrated
olt T-wave alternans in subjects with congestive heart failure.learly when comparing the predictive value of MTWA
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Microvolt T-Wave Alternans Meta-Analysis July 5, 2005:75–82esting among subjects post-MI, with CHF, or with a
istory of ventricular arrhythmias (Table 4, Fig. 3). The
nterpretation of results from MTWA testing in the
ndividual patient must be integrated with the clinical
istory of that patient.
Inconsistency remains in current practice as to whether an
ndeterminate MTWA test should be considered abnormal
r excluded altogether. Comparing the predictive value
f a bno rma l MTWA in th e e i gh t s t ud i e s
17,23,24,26,30,32,33,40), which provided outcomes based
n the inclusion or exclusion of indeterminate MTWA, we
ound no significant difference in the predictive value of an
bnormal test. Although statistically it seems that including
n indeterminate MTWA test as abnormal does not change
he predictive accuracy of the test, this does not necessarily
ndicate that an indeterminate MTWA test should be
onsidered abnormal. Fundamentally, it seems erroneous to
onsider a test that is, for example, uninterpretable because
f noise as clinically relevant. It remains important to
evelop and study alternative methods of assessing MTWA
e.g., dobutamine-induced) to risk stratify the patients who
ay have an indeterminate exercise-induced MTWA test
as many as 50% of patients in our review).
There are several strengths of this meta-analysis of
TWA. First, all of the studies were consistent in their
efinition of the presence, absence, or indeterminacy of
ignificant T-wave alternans based on the current standard
f T-wave alternans as developed by Rosenbaum et al. (6).
he exception to this was the study of Tapanainen et al.
40), which introduced the concept of T-wave alternans
esting incomplete. However, including or excluding the
roup of patients from this study with an incomplete
TWA test in our meta-analysis did not change the results
f the sensitivity analysis. Second, all of the studies were
onsistent in the use of the CH2000 (Cambridge Heart
nc., Bedford, Massachusetts) device for exercise-induced
TWA testing. Finally, we assessed the value of MTWA
esting in a wide variety of patient populations.
tudy limitations. There are several limitations to this
tudy. First, there were not sufficient data contained in the
ncluded multivariate analyses to determine the incremental
rognostic value of MTWA independent of other predic-
ors of arrhythmic events, such as EF, signal-averaged
CG, heart rate variability, or electrophysiologic study.
lthough MTWA seems clinically useful in this meta-
able 4. Summary Estimates of PPV, NPV, and Univariate RR i
rediction of Primary versus Secondary Arrhythmic Events
Summary Estimates
PPV
(95% CI)
NPV
(95% CI)
econdary event 51.0 (45.1–56.9) 86.0 (82.0–90.
rimary event 15.4 (13.8–17.0) 98.1 (97.5–98.
CHF, primary event 20.9 (17.8–24.0) 96.3 (94.8–97.
Post-MI, primary event 6.0 (4.5–7.4) 99.4 (98.9–99.
I  confidence interval; other abbreviations as in Tables 2 and 3.nalysis, the test may offer little additional predictive value
i
meyond other commonly used clinical predictors. Second,
he end points of the individual studies used in the summary
alculations were variable (e.g., cardiac death vs. SCD/
T/VF vs. syncope/VT). It may be more clinically applica-
le for future studies of MTWA to use the end point of
ardiac death, as was used in the study of Bloomfield et al.
33) and the study of signal-average ECG of Gomes et al.
42). Third, the subjects in the included studies were
rimarily men. For this reason, the results of this analysis
ay not be applicable to the general population. Fourth,
here was inconsistency in the exclusion of subjects using
eta-blockers or antiarrhythmic agents in the included
tudies. Because beta-blockers and antiarrhythmic agents
an decrease the sensitivity of MTWA (43–45), it is
ossible that this biased the results of our study. Finally, as
ith any meta-analysis, its quality is limited by the quality of
he included studies. However, eliminating the studies
onsidered to be of lower quality by our quality assessment
id not affect the outcomes of our analysis.
onclusions. We studied the use of MTWA as a predictor
f arrhythmic events in a meta-analysis of more than 2,600
ubjects. We found that the presence of MTWA predicted
nearly four-fold risk of an event compared with the
bsence of MTWA. The NPV of MTWA testing was 97%.
owever, the PPV of MTWA varied from 0% to 51%,
epending on the population of subjects studied. Given the
hallenge of risk stratification for life-threatening arrhyth-
igure 3. Positive predictive value of abnormal microvolt T-wave alternans
ospective Studies of Microvolt T-Wave Alternans for the
RR
(95% CI)
Average
Follow-Up (months) No. Studies
2.45 (1.53–3.95) 15 6
4.07 (2.35–7.06) 22 15
3.81 (1.86–7.82) 22 9
4.74 (1.11–20.19) 18 3n Pr
1)
7)
7)
9)n three populations of subjects. CHF  congestive heart failure; MI 
yocardial infarction.
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July 5, 2005:75–82 Microvolt T-Wave Alternans Meta-Analysisic events that faces today’s cardiologist and the economic
mplications for today’s society, our study helps understand
he value and the limitations of MTWA testing. Further
tudy of the combined predictive value of several methods of
isk stratification including MTWA with adequate
ollow-up and appropriate end points is warranted.
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